This story has been updated from a previous version.

NEW YORK, May 29 - Sequenom has agreed to acquire Gemini Genomics in a stock-for-stock deal valued at $238 million, the companies said Tuesday.   

The merger will leverage Sequenom's capabilities in large-scale genetic analysis with Gemini's databases of clinical and phenotypical information, the companies said.  

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.